. "[E09540D1B380]" . "Co vypov\u00EDd\u00E1 registr TULUNG o trendech ve vyu\u017Eit\u00ED n\u00E1kladn\u00E9 l\u00E9\u010Dby u NSCLC?"@cs . "14110" . "The authors discuss how current rules for administering pemetrexed, erlotinib, gefinitib, or bevacizumab influence their use in the treatment of advanced non-small cell cancer in the Czech Republic."@en . "RIV/00216224:14110/13:00070498" . . . "\u010Coupkov\u00E1, H." . . "I" . "Sixtov\u00E1, D." . "Gryg\u00E1rkov\u00E1, Y." . "Ko\u0161atov\u00E1, K." . "Co vypov\u00EDd\u00E1 registr TULUNG o trendech ve vyu\u017Eit\u00ED n\u00E1kladn\u00E9 l\u00E9\u010Dby u NSCLC?" . . "Va\u0161\u00E1kov\u00E1, M." . "Havel, L." . "22"^^ . . . "\u0160at\u00E1nkov\u00E1, M." . "Sk\u0159i\u010Dkov\u00E1, Jana" . "Hrn\u010Diarik, M." . "Bortl\u00ED\u010Dek, Zbyn\u011Bk" . "Kolek, V." . "TULUNG register; non-small cell cancer"@en . "Co vypov\u00EDd\u00E1 registr TULUNG o trendech ve vyu\u017Eit\u00ED n\u00E1kladn\u00E9 l\u00E9\u010Dby u NSCLC?"@cs . "Roubec, J." . . "What does the TULUNG register say on the trends in costly pulmonary onological treatment of advanced non-small cell cancer?"@en . . "Zemanov\u00E1, M." . "Co vypov\u00EDd\u00E1 registr TULUNG o trendech ve vyu\u017Eit\u00ED n\u00E1kladn\u00E9 l\u00E9\u010Dby u NSCLC?" . . "Hejduk, Karel" . . "Tom\u00ED\u0161kov\u00E1, Marcela" . "RIV/00216224:14110/13:00070498!RIV14-MSM-14110___" . "Zatloukal, P." . "Pe\u0161ek, M." . "Koubkov\u00E1, L." . . "Povoln\u00E1, Z." . "Salajka, F." . "Marel, M." . . "What does the TULUNG register say on the trends in costly pulmonary onological treatment of advanced non-small cell cancer?"@en . "Na stru\u010Dn\u00E9m shrnut\u00ED l\u00E9\u010Dby NSCLC v 1. linii prepar\u00E1ty, jejich\u017E pod\u00E1n\u00ED je v\u00E1z\u00E1no na p\u0159esnou mor-lologickou a genetickou diagnostiku, lze demonstrovat \u00FAskal\u00ED t\u00E9to n\u00E1kladn\u00E9 l\u00E9\u010Dby. To, \u017Ee se v \u010Cesk\u00E9 [republice v roce 2013 ji\u017E nenasazuje v 1. linii l\u00E9\u010Dby erlotinib, je zp\u016Fsobeno t\u00EDm, \u017Ee erlotinib nem\u00E1 stanovenou \u00FAhradu pro l\u00E9\u010Dbu v 1. linii. Od \u00FAnora 2011 ji m\u00E1 stanovenou gefitinib. V podstat\u011B bez probl\u00E9m\u016F jev prvn\u00ED linii zahajov\u00E1na l\u00E9\u010Dba pemetrexedem, proto\u017Ee sta\u010D\u00ED p\u0159esn\u00E1 morfologick\u00E1 diagn\u00F3za a l\u00E9k pat\u0159\u00ED mezi \u201Ecentrov\u00E9 l\u00E9ky%22, tedy hrazen\u00E9 mimo pau\u0161\u00E1l. Slo\u017Eit\u011Bj\u0161\u00ED je situace u bevacizumabu, proto\u017Ee do konce roku 2012, i kdy\u017E byla stanovena p\u0159esn\u00E1 diagn\u00F3za adenokarcinomu, byla l\u00E9\u010Dba hrazena z pau\u0161\u00E1lu pracovi\u0161t\u011B, co\u017E \u010Dinilo jeho pod\u00E1n\u00ED m\u00E9n\u011B dostupn\u00FDm. Limituj\u00EDc\u00EDm v p\u0159\u00EDpad\u011B gefitinibu je i p\u0159i dostupnosti molekul\u00E1rn\u011B genetick\u00FDch vy\u0161et\u0159en\u00ED p\u0159edev\u0161\u00EDm zisk kvalitn\u00EDho bioptick\u00E9ho vzorku a n\u00EDzk\u00E1 frekvence mutac\u00ED u b\u00EDl\u00E9 rasy." . . "4"^^ . "\u010Cernovsk\u00E1, M." . . . "Na stru\u010Dn\u00E9m shrnut\u00ED l\u00E9\u010Dby NSCLC v 1. linii prepar\u00E1ty, jejich\u017E pod\u00E1n\u00ED je v\u00E1z\u00E1no na p\u0159esnou mor-lologickou a genetickou diagnostiku, lze demonstrovat \u00FAskal\u00ED t\u00E9to n\u00E1kladn\u00E9 l\u00E9\u010Dby. To, \u017Ee se v \u010Cesk\u00E9 [republice v roce 2013 ji\u017E nenasazuje v 1. linii l\u00E9\u010Dby erlotinib, je zp\u016Fsobeno t\u00EDm, \u017Ee erlotinib nem\u00E1 stanovenou \u00FAhradu pro l\u00E9\u010Dbu v 1. linii. Od \u00FAnora 2011 ji m\u00E1 stanovenou gefitinib. V podstat\u011B bez probl\u00E9m\u016F jev prvn\u00ED linii zahajov\u00E1na l\u00E9\u010Dba pemetrexedem, proto\u017Ee sta\u010D\u00ED p\u0159esn\u00E1 morfologick\u00E1 diagn\u00F3za a l\u00E9k pat\u0159\u00ED mezi \u201Ecentrov\u00E9 l\u00E9ky%22, tedy hrazen\u00E9 mimo pau\u0161\u00E1l. Slo\u017Eit\u011Bj\u0161\u00ED je situace u bevacizumabu, proto\u017Ee do konce roku 2012, i kdy\u017E byla stanovena p\u0159esn\u00E1 diagn\u00F3za adenokarcinomu, byla l\u00E9\u010Dba hrazena z pau\u0161\u00E1lu pracovi\u0161t\u011B, co\u017E \u010Dinilo jeho pod\u00E1n\u00ED m\u00E9n\u011B dostupn\u00FDm. Limituj\u00EDc\u00EDm v p\u0159\u00EDpad\u011B gefitinibu je i p\u0159i dostupnosti molekul\u00E1rn\u011B genetick\u00FDch vy\u0161et\u0159en\u00ED p\u0159edev\u0161\u00EDm zisk kvalitn\u00EDho bioptick\u00E9ho vzorku a n\u00EDzk\u00E1 frekvence mutac\u00ED u b\u00EDl\u00E9 rasy."@cs . . "65848" .